Corporate profile
Grünenthal is a global leader in pain management and related disease.
We have a long track record of bringing innovative treatments to patients worldwide. As a fully integrated pharmaceutical company, we cover the entire value chain – from drug research and development to commercialisation of portfolios with growth products and established medicines. We operate in accordance with the highest ethical and regulatory standards, and we focus our efforts on our vision of a World Free of Pain.
employees worldwide
billion euros in 2023
countries across Europe, Latin America, and the US
countries
R&D sites – one R&D Unit in Aachen (Germany) and an Innovation Hub in Boston, (USA)
manufacturing sites in Europe and Latin America
Our unique commitment
Pain is a huge burden. It impacts patients – as well as their families, friends, caregivers and society as a whole. 75 years of developing innovative medicines for patients, we are driven to seek new solutions to relieve pain.
Responsibility
At Grünenthal, conducting our business responsibly is a core part of our company’s strategy and culture. As a global leader in pain management, Grünenthal aspires to create a positive impact for society – in our core business and beyond. We are guided by integrity, transparency and the highest ethical standards.
Global capabilities
Although firmly rooted in Germany, today we are very much a growing global business: since spreading our wings beyond Germany in the 1960s, we have continued to grow steadily and expand our market presence and product portfolio. We collaborate with commercial partners and multiple stakeholders from the pain management field and beyond in order to make our medicines available to patients.
Pipeline
To move closer to our vision of a world free of pain, we are currently pursuing a range of programs across different modalities, targets, and mechanisms of action. Here are some selected highlights from our development pipeline: RTX (resiniferatoxin), MPC-06-ID, Glucocorticoid Receptor Modulator (GRM), Nociceptin/Orphanin FQ receptor Peptide agonist (NOP).